Abstract
Recent interest in therapeutic developments for ankylosing spondylitis has focused primarily on two anti-tumor necrosis factor-α therapies, infliximab and etanercept, with several reports establishing their efficacy in pivotal phase III trials. Open extension analyses of earlier controlled trials have also shown that efficacy is maintained for at least 3 years, that monotherapy is adequate, and that treatment is well tolerated with few serious infections. Treatment is associated with reduction in sick leave and days spent in hospital. Despite induction of antinuclear antibodies and anti-ds DNA antibodies, clinical sequelae are rare. Reduction in magnetic resonance imaging parameters of inflammation and serologic biomarkers of cartilage turnover suggest that these agents may be disease-modifying though direct evidence from plain radiographic studies is still lacking. Conventional second line therapies typically used in rheumatoid arthritis have also been examined and while leflunomide appears to possess limited efficacy, there may be a case for re-examining the value of methotrexate.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Davis JC Jr, van der Heijde D, Braun J, et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 2003, 48:3230–3236. This pivotal phase III trial of etanercept in AS provides unequivocal evidence in support of the short term efficacy and safety of etanercept for the symptomatic treatment of patients with AS.
Baraliakos X, Tsuji W, Whitemore J, et al.: Magnetic resonance imaging examination of the spine in patients with ankylosing spondylitis before and after therapy with the TNF-alpha receptor fusion protein-etanercept. Arthritis Rheum 2004, 50(Suppl):L1.
Davis JC, van der HeijdeDM, Braun J, et al.: Sustained efficacy of etanercept in ankylosing spondylitis up to 18 months. Arthritis Rheum 2004, 50(Suppl):S611.
Van derHeijde D, Dijkmans B, Geusens P, et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a 24-week randomized placebo-controlled trial (ASSERT). Ann Rheum Dis 2004, 63(Suppl 1):SAT0053.
Calin A, Dijkmans BA, Emery P, et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004, 63:1594–1600.
Braun J, Brandt J, Listing J, et al.: Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005, 64:229–234.
Baraliakos X, Brandt J, Listing J, et al.: Clinical response to long-term therapy with infliximab in patients with ankylosing spondylitis-results after 3 years. Arthritis Rheum 2004, 50(Suppl):S217.
Baraliakos X, Brandt J, Listing J, et al.: Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Rheum 2004, 50(Suppl):S216.
Baraliakos X, Brandt J, Listing J, et al.: Two-year follow up results of a double-blind placebo-controlled trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2004, 50(Suppl):S615.
Listing J, Brandt J, Rudwaleit M, et al.: Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004, 63:1670–1672.
Ferraro-Peyret C, Coury F, Tebib JG, et al.: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004, 6:R535-R543. omprehensive prospective study describing the development of antinuclear and antiphospholipid antibodies in patients with RA and AS
Kobelt G, Andlin-Sobocki P, Brophy S, et al.: The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology 2004, 43:1158–1566.
Rudwaleit M, Listing J, Brandt J, et al.: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63:665–670.
Rudwaleit M, Schwarzlose S, Listing J, et al.: Is there a place for magnetic resonance imaging (MRI) in predicting a major clinical response (BASDAI 50) to TNF alpha blockers in ankylosing spondylitis? Arthritis Rheum 2004, 50(Suppl):S211.
Brandt J, Listing J, Sieper J, et al.: Development and preselection of criteria for short-term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004, 63:1438–1444.
Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002, 359:1187–1193.
Gorman JD, Sack KE, Davis JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α.N Engl J Med 2002, 346:1349–1356.
Yang C, Gu J, Rihl M, et al.: Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004, 51:691–699.
Vandooren B, Kruithof E, Yu DTY, et al.: Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor blockade in spondylarthropathy. Arthritis Rheum 2004, 50:2942–2953. etailed prospective assessment of synovial tissue, synovial fluid, and peripheral blood biomarkers in patients with AS and the response to infliximab therapy
Maksymowych WP, Poole AR, Webb A, et al.: Etanercept suppresses collagenase generated type II collagen neoepitope and increases cartilage proteoglycan turnover epitope in patients with ankylosing spondylitis. Arthritis Rheum 2004, 50(Suppl):S218.
Keller C, Webb A, Davis J: Cytokines in the seronegative spondyloarthropathies and their modulation by TNF blockade: a brief report and literature review. Ann Rheum Dis 2003, 62:1128–1132.
Stone MA, Payne U, Pacheco-Tena C, Inman RD: Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004, 63:84–87.
Haibel H, Brandt HC, Rudwaliet M, et al.: Efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: preliminary results of an open-label, 20-week trial. Arthritis Rheum 2004, 50(Suppl):S217.
Haibel H, Rudwaleit M, Listing J, et al.: Open-label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005, 64:296–298.
Tan AL, Marzo-Ortega H, O’Connor P, et al.: Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004, 63:1041–1045.
Haibel H, Rudwaleit M, Braun J, et al.: Six month open label trial of leflunomide in ankylosing spondylitis. Ann Rheum Dis 2005, 64:124–126.
VanDenderenJC, Van der Paardt M, Nurmohamed MT, et al.: Double-blind study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2004, 63(Suppl 1):SAT0033.
Wei JC, Chan TW, Lin HS, et al.: Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 2003, 30:2627–2631.
Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-del-Mercado M, et al.: Efficacy of methotrexate in ankylosing spondylitis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2004, 31:1568–1574.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maksymowych, W.P. Novel therapies for ankylosing spondylitis. Curr Rheumatol Rep 7, 182–187 (2005). https://doi.org/10.1007/s11926-996-0037-z
Issue Date:
DOI: https://doi.org/10.1007/s11926-996-0037-z